SHERIDAN, WYOMING – May 27, 2025 – Roche has received FDA approval for Susvimo® (ranibizumab injection) 100 mg/mL as a new treatment for diabetic retinopathy (DR), marking a pivotal advancement in the battle against this vision-threatening condition that affects nearly 10 million Americans.
SHERIDAN, WYOMING – May 27, 2025 – Roche has announced an encouraging update on its supplemental Biologics License Application (sBLA) for Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx), following discussion by the FDA’s Oncologic Drugs Advisory Committee (ODAC). The combination therapy demonstrated a significant 41% reduction in the risk of death in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not candidates for autologous stem cell transplant.
SHERIDAN, WYOMING – May 27, 2025 – Roche has announced FDA approval of its VENTANA® MET (SP44) RxDx Assay, marking a major milestone in companion diagnostics for non-small cell lung cancer (NSCLC). This approval paves the way for a more precise identification of patients eligible for AbbVie’s Emrelis™ (telisotuzumab vedotin-tllv), a targeted therapy for non-squamous NSCLC with MET protein overexpression.
Enhancing Treatment Precision in Lung Cancer Care
SHERIDAN, WYOMING – May 27, 2025 – Roche has announced compelling final results from the decade-long APHINITY Phase III clinical trial, demonstrating a significant 17% reduction in the risk of death for patients with HER2-positive early-stage breast cancer who received a Perjeta® (pertuzumab)-based adjuvant therapy. These findings reinforce the strategic role of the Perjeta-based regimen in long-term disease management and will be presented as a late-breaking abstract at the 2025 ESMO Breast Cancer Congress.
SHERIDAN, WYOMING – May 27, 2025 – Roche has introduced its Elecsys® PRO-C3 diagnostic test, marking a major step forward in the assessment of liver fibrosis severity, particularly in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). With the ability to deliver results in just 18 minutes, the new test is poised to streamline diagnostics and enable earlier, more accurate clinical decision-making.
Strategic Response to a Global Health Burden
SHERIDAN, WYOMING – May 19, 2025 – Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, has announced the successful completion of a $250 million strategic investment from global investment powerhouse KKR. The transaction marks a pivotal growth move, with KKR acquiring approximately 12% of Henry Schein’s common shares and strengthening its governance role with the appointment of two prominent executives to the company’s Board of Directors.
SHERIDAN, WYOMING – May 19, 2025 – Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, will present at the Jefferies Global Healthcare Conference on June 4, 2025. The event will be held at the Marriott Marquis in New York City, with Henry Schein’s session scheduled for 1:20 p.m. Eastern Time.
SHERIDAN, WYOMING – May 19, 2025 – Royal Philips has announced the European launch of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter, marking a significant step in transforming structural heart procedures through minimally invasive, real-time imaging technology. Already established in the U.S. market, this cutting-edge device supports more efficient, patient-friendly interventions without requiring general anesthesia — a major development for healthcare providers facing rising demands in structural heart disease care.
SHERIDAN, WYOMING – May 19, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the successful pricing of a €1 billion dual-tranche bond issuance under its European Medium Term Note (EMTN) program, marking a strategic step to reinforce its capital structure and advance sustainable investment goals.
SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation has achieved a historic milestone in genomic medicine, enabling the development and delivery of the world’s first personalized mRNA-based CRISPR therapy for an infant with a life-threatening genetic disorder—in under six months. Powered by the Danaher Business System (DBS), this breakthrough exemplifies how disciplined innovation and cross-company collaboration can dramatically accelerate biopharmaceutical timelines and patient impact.
Compressing an 18-Month Timeline into Six